Balanced news tone
News Sentiment
ADXN sentiment intelligence
Addex Therapeutics Ltd news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
76/100 classification confidence.
directly relevant articles
high-authority source matches
+9.5% over one week, -1.7% over four weeks, trend inactive, and below fair value.
How Addex Therapeutics Ltd (ADXN) Affects Rotational Strategy Timing
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Responsive Playbooks and the ADXN Inflection
Addex Therapeutics Ltd (NASDAQ: ADXN) is showing weak sentiment across all horizons, supporting a short bias, with an "exceptional 54.5:1 risk-reward short setup." AI models have generated three trading strategies: a position trading strategy, a momentum breakout strategy, and a
- Tone
- Negative 28/100
- Event
- Market update
- Published
- 20 Jun 2026 06:39
- Source
- Stock Traders Daily
Addex Therapeutics (ADXN) Holds Steady – Consolidation Near Support May Signal Next Move - Force Index
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jun 2026 07:00
- Source
- DonanımHaber
Addex Convenes Annual General Meeting 2026
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 Jun 2026 05:00
- Source
- GlobeNewswire
Addex Therapeutics Q1 2024 Earnings: Continued R&D Spending Weighs on Bottom Line as Pipeline Progresses - One-Time Gain Impact
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 29 May 2026 07:00
- Source
- dars.gov.et
Addex Therapeutics (ADXN) Drops 2.49%, Hovers Near Key Support at $6.32 - Intraday Profile
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 May 2026 07:00
- Source
- dars.gov.et
Addex Therapeutics (ADXN) Drops 2.49%, Hovers Near Key Support at $6.32 - Covered Call Trade
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 May 2026 07:00
- Source
- DonanımHaber
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Addex Therapeutics H2 2025 Earnings Call Transcript
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 01 May 2026 07:00
- Source
- MarketBeat
Addex Reports Full Year 2025 Financial Results and Provides Corporate Update
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 30 Apr 2026 05:00
- Source
- GlobeNewswire
Addex GABAB PAM Candidate Demonstrates Solid Anti-Tussive Activity in Bleomycin IPF-Related Chronic Cough Model
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Apr 2026 05:00
- Source
- GlobeNewswire
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Addex Spin-Out Company Neurosterix on Track to Complete Phase 1 Clinical Study of NTX-253 for Schizophrenia in Q2 2026
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Apr 2026 05:00
- Source
- GlobeNewswire
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 Apr 2026 05:00
- Source
- GlobeNewswire
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
Addex Therapeutics (ADXN) Stock Price, News & Analysis
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Apr 2025 04:35
- Source
- Stock Titan
Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 31 Jan 2024 08:00
- Source
- GlobeNewswire
Gout Therapeutics Market Size, Share | CAGR of 8.6%
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Aug 2019 18:22
- Source
- Market.us